Skip to content
New users? Get 5% off on your first purchase.
Free US shipping over $100
New users? Get 5% off on your first purchase.
Free US shipping over $100

Added to your cart:

Cart subtotal

Synagis palivizumab 100mg/1 mL Single-Dose Vial

SKU 66658-0231-01
Sale 13%
Original price $ 5,600.95
Current price $ 4,900.00
*Mountainside Medical does not fill personal prescriptions Medical Professional License Required to Unlock Account

How to Order:

Send an email request to: sales@mountainside-medical.com

You will receive instructions on how to create an account along with Rx Ordering Details.

(Note: Acceptable licenses must have Prescriptive Authority in the license issuing state.)
Fast Delivery
Fast Delivery
24/7 Support
24/7 Support
Easy Returns
Easy Returns
Hospital Grade
Hospital Grade
Save 13% ($ 700.95)
Free Shipping on orders $100
Returns 30-day return / replacement
Payment Secure transaction
Packaging Ships in product packaging
Service-Disabled Veteran-Owned Small Business
Service-Disabled Veteran-Owned Small Business
Located in Adirondack Mountains in NY
Located in Adirondack Mountains in NY
Family Owned Business 2002
Family Owned Business 2002
Sale 13%
Original price $ 5,600.95
Current price $ 4,900.00
Free Shipping on orders $100
Returns 30-day return / replacement
Payment Secure transaction
Packaging Ships in product packaging
Synagis palivizumab 100mg/1 mL Single-Dose Vial
Synagis palivizumab 100mg/1 mL Single-Dose Vial
$ 5,600.95 $ 4,900.00
🔒 Medical License Required
Description

Synagis is the only FDA-approved monoclonal antibody to help protect high-risk infants against RSV.

Synagis palivizumab 100mg/1 mL Single-Dose Vial is a highly effective medication used to prevent serious respiratory infections in infants and young children caused by the respiratory syncytial virus (RSV). RSV is the most common cause of bronchiolitis and pneumonia in children under the age of one, making it a significant health concern for parents and healthcare providers. Synagis works by targeting the RSV virus and preventing it from replicating, therefore reducing the risk of severe lung infections. This medication has been shown to significantly reduce hospitalizations and even deaths in premature infants and children with lung or heart conditions. Its convenient single-dose vial form makes it easy to administer and its recommended dosage of once a month for a total of 5 doses during RSV season offers excellent protection. The benefits of Synagis palivizumab 100mg are clear, as it not only protects against potentially life-threatening infections, but also provides peace of mind for parents knowing their child is receiving the best prevention possible for RSV.

Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.

Indications:

  • Synagis 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:
  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

Search Any Type of Product, Medication, or Alignment

Get Notified When Back in Stock